bioSyntagma
BioSyntagma is a platform that generates a multi-omic, spatial cell profile to understand cancer in patients and provides an AI-based treatment plan. The company's contact modes are mail and physical address.
Industries
Nr. of Employees
small (1-50)
bioSyntagma
Products
Molecular Fingerprint™ (mPrint) technology
A spatial workflow for mapping tumor microenvironments using PCR panels, sequencing, and imaging, designed for clinical samples and diagnostic applications.
AI-Guided Treatment Plans
Uses biomarker network maps to predict drug resistance in cancer patients and recommend treatment plans.
Biomarker Discovery
Services and collaborations for mapping biological system heterogeneity and discovering translational research biomarkers.
Companion Diagnostics
In-situ, multi-omic measurements for identifying patients likely to respond to immuno-therapies, crucial for clinical trial enrollment.
High-throughput SARS-CoV-2 detection method
A method developed with Takara Bio USA for rapid, large-scale COVID-19 testing using real-time PCR.
Molecular Fingerprint™ (mPrint) technology
A spatial workflow for mapping tumor microenvironments using PCR panels, sequencing, and imaging, designed for clinical samples and diagnostic applications.
AI-Guided Treatment Plans
Uses biomarker network maps to predict drug resistance in cancer patients and recommend treatment plans.
Biomarker Discovery
Services and collaborations for mapping biological system heterogeneity and discovering translational research biomarkers.
Companion Diagnostics
In-situ, multi-omic measurements for identifying patients likely to respond to immuno-therapies, crucial for clinical trial enrollment.
High-throughput SARS-CoV-2 detection method
A method developed with Takara Bio USA for rapid, large-scale COVID-19 testing using real-time PCR.